ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Michel Carrier
Louis P. Perrault
Duncan J. Stewart
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carrier, M.
Right arrow Articles by Pelletier, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carrier, M.
Right arrow Articles by Pelletier, C. L.

Ann Thorac Surg 1993;55:490-492
© 1993 The Society of Thoracic Surgeons

Articles

Pentoxifylline decreases cyclosporine-induced renal endothelin release and vasoconstriction

Michel Carrier, MD*, Louis P. Perrault, MD, François Tronc, MD, Duncan J. Stewart, MD, Conrad L. Pelletier, MD

Department of Surgery, Montreal Heart Institute, and Department of Medicine, Royal Victoria Hospital, Montreal, Quebec, Canada

Accepted for publication June 8, 1992.

* Address reprint requests to Dr Carrier, Department of Surgery, Montreal Heart Institute, 5000 Belanger St East, Montreal, Que, Canada H1T 1C8.

Cyclosporine (CSA) causes an acute vasoconstriction of renal artery and a significant increase in renal endothelin release. Pentoxifylline, a vasodilator, has been suggested to prevent CSA toxicity. To study the effect of pentoxifylline treatment on CSA-related vasoconstriction and endothelin release, a model of renal autoperfusion in the dog was used. Oral pentoxifylline at the dose of 400 mg three times daily for 3 days was given to 15 dogs. Pure powder CSA (10 mg) was injected into the isolated renal artery perfused at constant flow; changes in perfusion pressure reflected variations in vascular resistance. In the pentoxifylline-treated group (15 dogs), the infusion of CSA caused an average increase of 27 ± 8 mm Hg in renal perfusion pressure, compared with 60 ± 10 mm Hg in a control group of 8 untreated animals (p ≤ 0.05). Plasma concentration of endothelin in the renal vein increased from an average of 1.2 ± 0.2 pg/mL before to 2.4 ± 0.5 pg/mL after CSA administration (p ≤ 0.05) in the control group, whereas it did not change significantly in the pentoxifylline-treated group. Thus, oral pretreatment with pentoxifylline significantly decreased the renal vasoconstriction and endothelin release due to CSA administration.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
K. Okabayashi, M. Aoe, S. R. DeMeester, J. D. Cooper, and G. A. Patterson
Pentoxifylline reduces lung allograft reperfusion injury
Ann. Thorac. Surg., July 1, 1994; 58(1): 50 - 56.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1993 by The Society of Thoracic Surgeons.